Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
79.57
+1.28 (1.63%)
Oct 6, 2026, 4:00 PM EDT - Market closed
Monopar Therapeutics Market Cap
Monopar Therapeutics has a market cap or net worth of $534.09 million as of October 6, 2026. Its market cap has decreased by -25.41% in one year.
Market Cap
534.09M
Enterprise Value
399.99M
1-Year Change
-25.41%
Ranking
Category
Stock Price
$79.57
ChartMarket Cap Chart
Since December 19, 2019, Monopar Therapeutics's market cap has increased from $276.16M to $534.09M, an increase of 93.40%. That is a compound annual growth rate of 10.18%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 6, 2026 | 534.09M | 22.39% |
| Dec 31, 2025 | 436.37M | 225.25% |
| Dec 31, 2024 | 134.17M | 2,552.79% |
| Dec 29, 2023 | 5.06M | -83.48% |
| Dec 30, 2022 | 30.62M | -24.23% |
| Dec 31, 2021 | 40.42M | -42.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 19, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Phathom Pharmaceuticals | 549.66M |
| MapLight Therapeutics | 545.75M |
| Valneva SE | 540.23M |
| Oculis Holding AG | 538.92M |
| Altimmune | 532.01M |
| Prime Medicine | 530.15M |
| Capricor Therapeutics | 520.34M |
| ProKidney | 519.99M |